Innovation Kyoto 2021 Investment Limited Partnership ("KYOTO-iCAP No.2 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) as the general partner, has made a additional investment in RadioNano Therapeutics Inc. ("RadioNano Tx" Head office: Sakyo-ku, Kyoto; Representative Director: Masatoshi Chiba) through a third-party allocation of new shares.

Overview of this investment
RadioNano Tx was established in April 2024 by Masatoshi Chiba, President, and Hiroshi Kawai, Director, under the auspices of Kyoto iCAP, with the aim of implementing BNCT (Boron Neutron Capture Therapy) using novel highly hydrophilic boron-containing inorganic nanoparticles (RN-501) developed by Professor Naoki Komatsu, Graduate School of Human and Environmental Studies, Kyoto University, and Professor Minoru Suzuki, Composite Nuclear Science Institute, Kyoto University, for society. The company was established in April 2024 by Masatoshi Chiba, President, and Hiroshi Kawai, Director, with the support of Kyoto iCAP, with the aim of implementing BNCT (Boron Neutron Capture Therapy) in society.

In addition to the joint research by Professor Komatsu and Professor Suzuki, Kyoto University has been verifying the validity of the start-up establishment and demonstrating that RN-501 induces potent cancer cell killing and cancer immunity as a cancer therapeutic agent used in BNCT by utilizing the "feasibility study" R&D fund under the National Institute of Science and Technology Agency's New Industry Creation Fund for University-Launched Science and Technology project. In addition, we have demonstrated that RN-501 induces potent cancer cell-killing and cancer immunological effects as a cancer therapeutic agent used in BNCT.

RadioNano Tx has taken over these research results from Kyoto University and has established a research and development system for boron inorganic particles optimized for BNCT with Prof. Komatsu and Prof. Suzuki as scientific and technical advisory board members. With this funding, the company aims to proceed with non-clinical testing of RN-501 and start clinical trials.

Kyoto iCAP has invested an additional ¥200 million in RN-501, which is being developed by Kyoto University and RadioNano Tx, in the hope that it and its underlying technology will provide a new cancer treatment option. In addition to Kyoto iCAP, Mitsubishi UFJ Capital Limited, DBJ Capital Limited, and the Japan Science and Technology Agency participated in the private placement of approximately 450 million yen in total by RadioNano Tx. Additional funding is planned for around the end of the year, and discussions are currently underway with several investors.

RadioNano TherapeuticsAbout the Corporation
Establishment : April 1, 2024
Nature of Business: Research and development of highly hydrophilic inorganic nanoparticle products
Head Office: 36-1, Yoshida Honmachi, Sakyo-ku, Kyoto, Japan
Representative Director : Masatoshi Chiba, PhD
HP : https://www.radionano-tx.com/

Kyoto University Innovation Capital Corporation (Kyoto) iCAPAbout
As a wholly-owned subsidiary of Kyoto University, Kyoto iCAP invests in and provides other business support to companies that utilize research results generated at Kyoto University and other national universities. The firm currently operates the Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No. 1 Fund") (established in January 2016) with a total value of ¥16 billion and the KYOTO-iCAP No. 2 Fund (established in January 2021) with a total value of ¥18.1 billion. The KYOTO-iCAP 1 Fund has a maturity of up to 20 years, and the KYOTO-iCAP 2 Fund has a maturity of up to 17 years, enabling long-term support for the practical application of research results from Kyoto University, which has strengths in basic research. The KYOTO-iCAP 2 Fund has a maximum maturity of 17 years. In addition, a portion of the KYOTO-iCAP No. 2 Fund will be invested in national university-launched ventures outside of Kyoto University.

Contact information for inquiries
Kyoto University Innovation Capital Co., Ltd.
36-1, Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317, Japan
Osami Kono, Senior Officer, Business Development Department
E-mail: info@kyoto-icap.co.jp
TEL: 075-753-7588